Bridgewater Associates is one of the big cap hedge funds in the United States and Ray Dalio founded it in 1973. As per the recent SEC 13F filing of Bridgewater Associates on November 12, Apple Inc. (NASDAQ:AAPL), International Business Machines Corp. (NYSE:IBM), Gilead Sciences, Inc. (NASDAQ:GILD) are its top three stock holdings.
Apple Inc. (NASDAQ:AAPL) is the largest stock holding of Bridgewater Associates with 535,897 shares of the company at current market value of $53 million. Earlier, this year Apple Inc. (NASDAQ:AAPL) launched Apple Pay, mobile payment system, that uses NFC technology allowing users to make a payment by shaking their phone. The payment method has seen wide scale adaption including brands like McDonald’s Corporation (NYSE:MCD), Staples, Inc. (NASDAQ:SPLS), Nike Inc (NYSE:NKE), and RadioShack Corporation (NYSE:RSH). (Click here to check the list of all the major hedge funds holding positions in AAPL at the end of the second quarter)
International Business Machines Corp. (NYSE:IBM) comes at number two in Bridgewater Associates’ portfolio with 171,240 shares at current market value of $32 million. International Business Machines Corp. (NYSE:IBM) is now that #24th largest company in terms of its market capitalization at $162.52 billion surpassing Citigroup Inc (NYSE:C) at $161.77 billion. Berkshire Hathaway is the largest investor of International Business Machines Corp. (NYSE:IBM) including other investors such as Renaissance Technologies and Adage Capital Management.
Gilead Sciences, Inc. (NASDAQ:GILD) is the third largest stock holding of Bridgewater Associates with 241,521 shares of the company at current market value of $25 million. Gilead Sciences, Inc. (NASDAQ:GILD) filed application with the U.S. Food and Drug Administration for the treatment of HIV-1 infection, as the drug reflected significant viral suppression and improved bone safety during the third phase of the study. The shares of Gilead Sciences, Inc. (NASDAQ:GILD) trade at $100.43 with current market cap of $153.20 billion. Â The shares of the medical company have grown 33.61% year-to-date.
This article has been written by Prakash Pandey.
